Baudax Bio Inc. (BXRX)

Closing of $5 million Public Offering is Announced


Gregory AurandMedia Inquiries
Senior Healthcare Services & Medical Devices Analyst
December 7, 2022
Report ID: 25450
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Baudax Bio Inc.
Baudax Bio Inc.
Healthcare
Biotechnology
Ticker
BXRX
Current Price
$1.79 -6.77%
Market Cap
$4.6M
Price Target
Refer to Report
Volume
1.4M
52wk Range
$1.25 - $91.2
Related Research Reports
2/24/2023

Fourth Quarter and Full Year 2022 Reported
Fourth Quarter and Full Year 2022 Reported (BXRX)
1/25/2023

Baudax Bio Announces Positive Interim Analysis Of BX1000 Phase II Trial
Baudax Bio Announces Positive Interim Analysis Of BX1000 Phase II Trial (BXRX)
1/3/2023

Baudax Bio Discontinuing ANJESO Sales; Reducing Rating To Market Perform
Baudax Bio Discontinuing ANJESO Sales; Reducing Rating To Market Perform (BXRX)
12/7/2022

Closing of $5 million Public Offering is Announced
Closing of $5 million Public Offering is Announced (BXRX)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.